Trial · NCT00423319
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Rate of Composite of Adjudicated Venous Thromboembolic Event (VTE)-Related (Pulmonary Embolism and Symptomatic and Asymptomatic Deep Vein Thrombosis[DVT]) and All-cause Death During the Intended Treatment Period | Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose | All randomized participants who, during the Intended Treatment Period, had an adjudicated and evaluable bilateral venogram, had an adjudicated venous thromboembolic event, or died of any cause. | Percentage of events/patients evaluated | NUMBER |
| SECONDARY | Rate of Composite of Adjudicated Proximal Deep Vein Thrombosis (DVT), Nonfatal Pulmonary Embolism, and Venous Thromboembolic Event-related Death With Onset During Intended Treatment Period | Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose | Randomized participants with either an adjudicated event or an adjudicated evaluable bilateral venogram | Percentage of events/patients evaluated | NUMBER |
| SECONDARY | Rates of Adjudicated All-cause Death, VTE-related Death, Pulmonary Embolism (PE), Nonfatal PE, Deep Vein Thrombosis (DVT) (Symptomatic and Asymptomatic), Symptomatic and Asymptomatic Proximal and Distal DVT During the Intended Treatment Period | Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose | All participants randomized to treatment | Percentage of events/patients evaluated | NUMBER |
| SECONDARY | Rate of Major Bleeding, Clinically Relevant Nonmajor Bleeding (CRNM), Major or CRNM, and Any Bleeding During the Treatment Period | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Percentage of events/patients evaluted | NUMBER |
| SECONDARY | Number of Participants With Serious Adverse Events (SAEs), Bleeding Adverse Events (AEs), and Death as Outcome | First dose of study drug (presurgery) through 30 days after the last dose of study drug | All participants who received at least 1 dose of study medication | Participants | NUMBER |
| SECONDARY | Number of Participants With a Bleeding-related Adverse Event During the Treatment Period | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Number of Participants With a Bleeding-related Adverse Events During the Treatment Period (Continued) | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Number of Participants With a Bleeding-related Adverse Event During the Treatment Period (Continued) | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Number of Participants With Neurologic Adverse Events With Onset During the Treatment Period | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued) | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Number of Participants With Marked Abnormalities (MA) in Clinical Laboratory Test Results During the Treatment Period (Continued) | First dose of study drug (presurgery) through 2 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Number of Participants With Adverse Events Related to Elevations in Liver Function Test Results With Onset During the Treatment Period | First dose of study drug (presurgery) through 30 days after the last dose of study drug | All participants who received at least 1 dose of study drug | Participants | NUMBER |
| SECONDARY | Rates of Adjudicated Myocardial Infarction (MI)/Stroke, MI, Stroke, and Thrombocytopenia During the Intended Treatment Period | Day 1 (first dose of study drug) to later of 2 days after last dose or 38 days after first dose | All participants who received at least 1 dose of study drug | Percent of events/patients evaluated | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00423319/outcomes